NEUROBLASTOMA UK FIGHTING CHILDHOOD CANCER NEUROBLASTOMA UK Charity Commission referen number: 326385 REPORTS AND FINANCIAL STATEMENTS For the year ended 31 December. 2025
NEUROBLASTOMA UK REPORT AND FINANCIAL STATEMENTS For the year ended 31 December, 2025 CONTENTS Page Trustees, annual report Indep8ndenl Examiner's Report SlateneTrt of Financial AclNilies Balance sheet Notes lo the financial ststements 9-12
TRUSTEES. ANNUAL REPORT for the year to 31 December. 2025 The Trustees present their report wtth the financial statements of the Charty for the year ended 31 December 2025. The Trustees have adopted the provisions of Accounting and Reporting by Charities.. Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Irelalld IFRS102) (effective 1 January. 20151. As a charity registered in England and Wales. the Charity also reports in accordance with the Charity Commission for England and Wales, guidan on public benefit and the Charities Act 2015. Section A nc mini iv Charity Name NEUROBLASTOMA UK Registered Charity Number 326385 Registered Address Canopi. 82 Tanner Street. London SE13GN Trustees who manage the Charity: Zara Ailchison (Cfrchairl Tori Eadinglon (Secretary) Malcolm Dean (Treasurer) Clair Cliff (Treasurer) Ruby Dickens Stephen Smith DeborahTweddle Faye Watts Kate Wheeler (Co-chair) Martin Elliott Independent Examiner DJH L5verpool Limited. Statutory Auditor. 3rf Flcw Pacific Chambets. 11-13 Victoria StreeL Liverpod. L2 5QQ Bardays Bank PLC. Newmarkel, LE87 28B Bankers Public Benefit Requlrement The Iruslees of Neuroblastoma UK confimi that they have complied with their duty to have due regard lo Ihe guidan on public benefit published by the Charity Commission in exercising their powets or duties. Section B StTUCt re ov mance and man ernen Governing Docurnent The Trust is an unincorporated trust. constiluted under a Trust Deed dated 20 May. 1983 and by the supplernental Deed of Amendment 9th September 2016 and is a registered Charity number 326385 in England and Wales. Recruitment and appointment of new trustees Lay TnJstees are appointed by the Trustees following considerab.on of appltcations received from individuals. Medical Trustees are appointed by ihe Trustees on the recommendation of existing Medical Trustees. Risk Management Trustees have considered the major risks to which the Charity may be exposed.. have reviewed them and estsbli5hed systems and procedures to manage them. Tnjslees consider the possibility that money placed on investment could be al risk if the organisalion holding the deposit should fail. Athough current investments are placed with large. well-eslablished financial institutions Trustees identified the need lo re-examine investment policy and have concluded that investments should be spread across a nurnber of institutions lo minimise the
impact if a single fund-holder should fail. The Trust is essenlially a cash based charity, holding no property. The Charity has developed sufficient inlemal controls to monitor and minimise the risk of misappropriation of funds. Section C es Oblectives and Alms The object of the Charity is to improve treatments and outcomes for all children suffefing with neuroblasloma. and lo achieve this we raise funds for vital mediral searCh. The Charity also raises awareness of the disease, advocates for impmved accessibility to treatments and provides infomiatH)n and support to families. Policy on Grant-making Trustees invite applications for grant awards by public advertisement. typically on the Charity's website. Normally this is biennially so that sufficient funds are available to mmmission meaningful research studies, although exceptions are OccasionlY made when judged appropriate by Trustees in consullalion with the Charity's Scientific Advisory Board {SAB}- Applications are first considered by the Charity's SAB. which is made up of 5 scientists eXperiend in Neuroblasloma research and a chairnlan who is a paedialric oncology clinician. Each application is accompanied by reports from 2 or 3 referees who have specialist knoedge of the research area proposed, and by a response from the applicants to those reports. The SAB then recommends to Trustees applicaliorbs Worthy of grant funding in order of me¥it. Trustees award grants in the light of the SAB'S advice and funds available. Grants are only awarded to the extent that reswrces have already accrued in the Charity's unrestricted fijnd or appropriate restricted fvnd. Sgction D en nco Charitable Activitias 2024 was a year of signtficant spend for the Charity after hosting the Neuroblasloma UK Symposium and funding in excess of £1.1 m in new research studies for Neuroblasloma. The objective for 2025 was to replenish fu$ whilst continuing to advocate on behaw of the neuroblasloma community. raise awareness and fund small innovation sludies whilst building up our reserves for the next major grant round which we hope will be in 2027. We are delighted that our major research studies that were awarded at the end of 2024 , have all commenced during 2025 and will continue over the next 24 yeats . We received a grant to put towards our commitment to Professor Archibald's study al KCL in improvements in PET imaging of £125.(MJO (£62,500 in 20025 and the rest we should receFve in 2026 YOA) from Sofving Kbjs. Cancer UK suw)rted by funding from Children wrlh Cancer UK. We rebranded our 'Sm811 Granls. as 'lnnovation Grants. to reflect the inspiring novel applications that we receive. which often test bold new ideas. These grants. although small. have shown swjnificant impact and often act as ' proof of principle. research that ran pave the way for larger dinical studies. We awarded funding for 3 new studies in 2025. (£2,000 lo the ICR to invesligale better drug combination strategies for high risk neuroblastoma.Using advanced 3D tumour models to test combinations of ALK-blocking dS with ATR inhibitors to see which are the most effective against chemotherapy resistant tumours. £4.970 to University of Southampton to investigate tsting immune cel therapies for neuroblastoma which could strengthen future immunotherapy approaches. We were grateful for support from the Grocers Charity of £5.000 which funded Dr Wang's research also at Soulhamplon. This team of researchers rntlY discovered three sub groups within neuroblasloma that do not have MYCN amplification and this grant enabled them to IcN)k into polential new treatments for these sub groups.) Also in 2025 , we committed funding to support the BIOPORTAL project in excess of £25.000- the first UK data repository for children with neuroblastoma .A new edib.on of our free "Parents Guide lo Neuroblastoma" and our factsheel-Treatrnent options for relapsed or refractory high llsk neuroblastoma". online and in print. in collaboration with Children's Cancer and Leukaemia Group and Solving Kids Cancer UK . was released.
From an advocacy perspective we supported the Rare Cancer Bill and are delighted that it has now been given the final approval by the House of Lords. This calls for a look at unJenl dispartties in care . research and survival outcomes of CanrS that are perceived as 'rare'. We continue lo advocate as part of a collective voice with Canr 52 and One Cancer Voice. Neuroblasloma UK were proud lo present alongside 60 other charities a bold. fully fvnded National Canr Plan to Downing Street. This year we reSt¢tred our staffing as a small fvnctional unit wtth a new management position. Along with most charities, we have not been adverse to the tougher economic environment of the last few years and we hope that this new structure will improve our fvndrdising margins through a dear focus on financi targets and a strengthened strategic brand management. Our principal funding sources are voluntary donations and 2025 saw fundraising challenges from all over the British 151es from Kiltwalkers in Glasgow to coastsl runs in Boumemouth and Co Antn"m and past thè sights in London, Birmingham and more.The Three Peaks have been dimbed. 100km covered via bike,skydives completed. ball room dances, santa runs elc. 89 supporters look part in our'100 Miles in September. Challenge Comedy nights, bake sales and TedFesl our supporters have pulled out all the stops lo raise funds on our behalf. We are also grateful lo major donations from the John Biack Foundab'on. Robert Luff FourKlation and the Peter John Foord Charitable Twst. Significant fundraising events for us were the BBC Lifeline Appeal in January and February which aired on 8BC1 and the Big Give Christmas Chlenge with thanks to Georgia's Fund and Can(lis Publications. The major event of the year for the neuroblastoma communty was the final of'celebrity Traitors, watched by over 12 million and won by our own patron, Ajan Carr. Not only did this mean that we were the receiver of the prize pol bul over 137,000 people hit our website that night and 'neuroblasloma' was highlighted across the media. Whilst Alan won playing a dastardly Traitcff . he is forever faithfvl to our Cause. The Trustees express their gratitude to ALL parthefs . snSorS . volunteers, families and supporters whose amazing contributions have enabled Neuroblasloma UK to sustain and expand its work during the year. We remain faithfijl to finding a cure for neuroblasloma. Sectlon E Financi eview Reserves Policy The annual income generated by the Charity is to be applied for Charitable purposes in accordance with the Trust's objective. Year on year the trustees intend to make a full distribution of available income, subject to making adequate reserves for known and potential liabilities and commitments, where applicable. Any amounts not so distributed are accumulated in the unrestricted fund. Funds committed to supporting approved research. but not immediately required are invested in line wilh the investment poly described below. The balan held as unreslricled reserves al 31 December. 2025 was £105.77712024= 1£295,9471) and Trustees have agreed that £70,000 of reserves must be held lover and above the grant commrtmentsl to support 6 months of operalional expenditure. Investment Policy The Trustees, intention is lo maintain funds so Ihat they a readily acceble when required. bul are eaming a reasonable r@tum whilst nol ulilised.Trustees reviewed this policy in February 2005 and confirmed their policy of only placing funds in investments where the book value of the principal is maintained. Statement of Trustees Responsibilitles
The trustees are SnsIble for preparing the financial statements in accordan with applicable law and United Kingdom Accounting Standards (United Kingdom Generalty AcpIed Accour7ting Practice). Charity Law requires the Iruslees lo prepare financial statements for eath financial year. Under that law the trustees have elected lo prepare the financial slalements in accordance wtth the United Kingdom generally accepted accounting practi (United Kingdom Accounting Stsndards. c(¥npnsing FRS 102'The financial reporting standard applicable in the UK and Republic of Ireland.. and applicable lawl-The financial statements are required by law to give a true and lair view of the stsle of affairs of the charity and ofthe surpius or deficit of the charity for that period. In preparing ttre financial ststernenls the tnjslees are required lo.. * select suitable accounting policres and then aptdy them consistenlly, * observe the methods and prinryples in the Charibes SORP (FRS1021; * make judgements and estimates that are reasonable and pruden( + slate whether applicable a(xounling standards have been followed. subpct lo any material departures disclosed and explained in the financial statements- and + prepare the financial statements on the going concem basis unless it is inappropriate to presume that the Charity will continue in business. The Trustees are responsible for keeping proper accounting records whth disdose with reasonable accuracy the firiancial position of the Charity and to enable them to ensure that Ihe finanfial statements comply with the Charities Act 2011. the Charity (Accounts and ReFJOrts) Regulations 2008 and Ihe provisions of the trust deed.
They are also responsible lor safeguarding the assets of the Charity and hen for taking reasonable steps for the prevention and detection of fraud and other irregularities. Signed on their behalf and with their approval by.. MRS ZAITCHISON Chair MS CLAIR CLIFF Tnjslee and Treasurer
Independent Examlner's Report to the Trustees of Neuroblastoma UK I report to the trustees on the examinats.on of the accounts of NeuroblastomA UK for the year ended 31 December, 2025.. Respective Responsibilities of Trustees and Examiner The Charity's Iruslees are responsible for the preparation of accounts in accordance with the requiremenls of the Charities Act 2011. I have reported in respecl of the examination of the Charitys accounts carried out under section 145 of the 2011 Act and in carrying out the examination have followed all the applicable Directions given by the Charity Commission under section 145{51{bl of the Act. Independent Examiner's Ststement The Charity's gross income extEeded £250.0 and l am qualrfied to undertake the examinalion by being a qualified member of ICAEW. I have completed the examination and can confirm that no material matters have come lo my attention in connection with the examinab'on. which gives me reasonable cause to believe that in, any material respect.. the accounting records were not kept in accordance with sectton 130 of the Charities Act 2011., the accounts did not accord with the aceounting records" or the accounts did not comply wih the applicable requirements conMIng the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair, view which is not a matter considered as part of an independent examination. I have no cOnM$ and have come auoss no other matters in CA)nnection with the examination lo which attention should be drawn in this report in order to enable a proper understanding of the aCUnIS lo be reached. Mr M J Forshaw BA FCA DJH Liverpool Limited Pacific Chambers 11-13 Vidoria Street Liverpool L2 5QQ
NEUROBLASTOMA UK STATEMENT OF FINANCIAL ACTIVITIES YEAR ENDED 31 DECEMBER 2025 Unrestricted Funds 31 December. 2025 Unrestricted Funds 31 Dernber, 2024 Note INCOME AND ENDOWMENTS FROM: Donations 393.910 209,846 Other trading activities 52.628 46,985 Income from investments 44,459 46,519 TOTAL 490.997 303,350 EXPENDITURE ON: Raising funds 11,717) 1464) Charitable activities: Grants payable and grant amendments 29,178 11.012.496} Govemance costs 1116.734) 1172,3851 TOTAL {89.273) (1.185,345) NETINCOME/(EXPENDITURE) 401.724 (881,9951 RECONCILIATION OF FUNDS Total funds brought forward {295.947) 586,048 TOTAL FUNDS CARRIED FORWARD 105.777 1295,9471 10
NEUROBLASTOMA UK BALANCE SHEET AS AT 31 DECEMBER 2025 2025 2024 Note CURRENT ASSETS Debtors and advance payments 17.730 24,664 Inveslnenls 10 1.083.649 1,250,792 Cash al bank 11 260.$30 100,743 TOTAL CURRENT ASSETS 1,361.909 1,376,198 CREDITORS." Amounts falling due within one year 12 {346.170) 1483,564) NET CURRENT ASSETS 1.015.739 892,634 CREDITORS.. Amounts falling due in more than one year 13 (909.962) {1.188,5811 NET ASSETS 105.777 1295,9471 FUNDS OF THE CHARITY Unrestricted fund 15 105,7ri (295.947) The financial statements sel out on pages 8- 13 were approved by the Trthstees on 23rd of July 26: TRUSTEE- Mrs Z Aitchison TRUSTEE- MS C Clair 11
EUR BLAST MA NOTES TO THE ACCOUNTS YEAR ENDED 31 DECEMBER 2025 ACCOUNTING POUCIES Basis of preparing the financial statements The financial ststemenls of the tharilable trust. whrch is a putAic trenefft entity under FRS 102, have been prepared in accordance with the Chalilies SORP (FRS102) 'Accounting and Reporting by Charities- Slalemenl of Recommended Practice applicable lo charities preparing their accounts in accordance with the Financial Reporting Stsndard applicable in the UK and Republic of Ireland IFRS1021 leffeclive 1 January. 2015).. the Finan(ial Reporttng Standard 102 (effective January 2015) and the Charities Act 2011. The finanaal statements have been wepared under the historical cost convention. Donations Cash donations and gift5 are included in full in the Statement of Financial Activities when they are received by the Charity. Cash collected al special fund-raising events included in the income and expenditure account after deducling the expenditure incurred directfy in staging the event. Significant non-cash donations are induded in the irtcome and expenditure aco)unt at the Trustees. estimation of their market value when received. Income from investments Investment income is induded in the Statement of Finan81 Acbvitres on an accruals basis. Research grant awards These are Charged to the Ststemenl of Finanoal Activtiies when the Tnjslees have awarded them. Research grants awarded. bul not disbursed at the balance sheet date. are carried forward as grant creditors in the balance sheet. Fund accounting Unrestricted fvnds can be used in accL)rdance wth the charitable cbjectives at the discretion of the trustees. Reslricled fijnds can only be used lor p8rts"cular restricted purposes wrthin the objects of the charity. Reslriclions arise when Sptfied by the don or when funds are Sed for parti¢Lrlar restricted purpDses. Further explanation of the nature and purpose of each fund Is inclL*Jed in the notes to the financial statements. Cash Ilow statements The Charity has taken advantage of the exemption provmled by the ch8rib.es SORP {FRS102) and does not prepare a cash ffow statement Taxation The Charity is exempt from tsxakn on its charttable activib"es. VAT As a non-trading organisation. the Charty is not registered for VAT purposes and is unable to recover VAT incuffed on its expenditure. 12
NEUROBLASTOMA UK ENDED 31 DEC 025 DONATIONS 2025 2024 Donations and fund-raising 393.910 209,846 OTHER TRADING ACTivfTIES 2025 2024 Christmas cards, webshop and other income 52,628 46.985 INCOME FROM INVESTMElffS 2025 2024 COIF deposit National saving5 income bonds 32,857 33.315 44.459 46,519 EXPENDrruRE ON RAISING FUNDS 2025 2024 Fund-raising a1 publicity Costs 1.717 464 GRANTS PAYABLE AND GRANT AMENDMENTS 2025 2024 Contribution from Medical Research Council Archibald Chesler Falconer Piskareva Stoker Wrillen Off Small Grants 189,8571 268.301 254,120 188,039 208,887 183,207 (62.500) 33.322 (29.1781 201 1.012,496 13
NEUR BLAST MAUK NOTES TO THE ACCOUNTS Contin ed YEAR ENDED 31 DECEMBER 2025 EXPENDITURE ON CHARITABLE ACTivmES 2025 2024 Rent and facilits.es Cambridge Symposium Staff salaries and penston contributions Sporting event costs Subscriplicffis Travel Computers. software and equipment hire Accounts and audit Tnjslees meeting costs Printing, postage and stationery Legal fees Sundries Advertising and website Insurance Bank and professional charges 8,310 8,573 38,893 96,072 5.407 4.734 76,T75 6.988 20 6.212 840 9,027 840 714 262 1,869 1.926 1.003 919 2.787 1.226 9,310 116,734 1.202 982 172.385 TRLISTEES, REMUNERATION AND BENEFITS There was no tTUStees' remuneration or other benefrts for the year ended 31 December, 2025 12024.. £NILI. The Trust owns no premises. DEBTORS AND PREPAYMEKrs 2025 2024 Receivables Prepayments Co-funding income 1,188 2,292 14.250 1.188 4,226 19,250 17,730 24,663 10. CURRENT INVESTMENTS 14
UROB STOMA NOTES TO THE ACCOUTrtrs Continued YEAR ENDED 31 DECEMBE 2025 11. CASH AT BANK AND IN HAND 2025 2024 Cash al Bank 260 530 100 742 12. CREDITORS- DUE WITHIN ONE YEAR 2025 2024 Grant commitments Trade creditors Accruals Co-funding income reNed in advan 300.654 4,202 26.314 465.696 1,966 900 15,000 346.170 483.562 13. CREDITORS- DUE IN MORE THAN ONE YEAR 2025 2024 Grant commitments 909.962 1,188,581 14. GRANT COMMITMENTS 2025 2024 Totsl commitments at 1 January. 2025 Paid in the year New commilments 1.654.479 1450,8041 7,142 670,328 1118,403} 1.102.554 1.210.817 1.654.479 All of the new grant commitrnents are to institutsons. 15. ANALYSIS OF UNRESTRICTED FUND 2025 2024 At 1 January. 2024 Net movement in funds for the year 1295.947) 401 724 586.048 881 995 105,77T {295,9471